Evidence Question
Does Semaglutide reduce cardiovascular risk?
Related to: Cardiovascular RiskShort answer
Semaglutide appears to reduce cardiovascular risk.
Evidence at a glance
- Evidence strength
- Strong Evidence
- Supporting research
- 11 studys
- Randomized trials
- 11 trials
Why do we say this?
Across 11 randomized trials, findings are consistent and showed an effect on cardiovascular risk with Semaglutide.
Explore the evidence
Supporting research
11 published studys
- Semaglutide improves kidney and cardiovascular outcomes in diabetes
- Semaglutide may reduce cardiovascular events in non-diabetic patients.
- Semaglutide improves cardiorenal outcomes in high-risk diabetes patients
- Oral semaglutide may improve cardiovascular event prevention in type 2 diabetes.
- HbA1c mediates cardiovascular benefits of GLP-1 receptor agonists